The FDA’s decision to skip an advisory panel may indicate that agency reviewers are more unified in their views of the Bluebird therapy. Or it could simply indicate a higher comfort level with the type of treatment Bluebird is developing; FDA committees unanimously backed two Bluebird gene therapies that are delivered in a similar way in June 2022, and both went on to win approval.
By contrast, Vertex and its partner are vying to market the first therapy based on CRISPR gene editing technology. Vertex CEO Reshma Kewalramani told investors on an Aug. 1 call that the decision to hold an advisory panel wasn’t surprising, “given the new mechanism of action.” The meeting will offer an opportunity to hear from patients and highlight the “transformative potential” of exa-cel, she said.
